Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania

American Journal of Tropical Medicine and Hygiene

Volumn 77, Issue 6, 2007, Pages 1060-1065

  Al Wabel, Mohammad A ^a   Tonui, Willy K ^b   Cui, Liwang ^c   Martin, Samuel K ^b   Titus, Richard G ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; NUCLEOSIDASE; PARASITE ANTIGEN; RECOMBINANT ENZYME; RECOMBINANT INTERLEUKIN 12; GLYCOSIDASE; INTERLEUKIN 12; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; PROTOZOAL VACCINE; RECOMBINANT PROTEIN; SUBUNIT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNE RESPONSE; INTERFERON PRODUCTION; LEISHMANIA MAJOR; MOUSE; NONHUMAN; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; ENZYMOLOGY; IMMUNOLOGY; ISOLATION AND PURIFICATION; SKIN LEISHMANIASIS; TIME;

ANIMALIA; LEISHMANIA MAJOR; MUS;

ANIMALS; ANTIGENS, PROTOZOAN; FEMALE; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; N-GLYCOSYL HYDROLASES; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; TIME FACTORS; VACCINATION; VACCINES, SUBUNIT;

EID: 39049127054     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2007.77.1060     Document Type: Article

References (33)

1. von Stebut E, Udey MC, 2004. Requirements for Th1-dependent immunity against infection with Leishmania major. Microbes Infect 6: 1102-1109.
2. Scott P, Artis D, Uzonna J, Zaph C, 2004. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol Rev 201: 318-338.
3. Gumy A, Louis JA, Launois P, 2004. The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds. Int J Parasitol 34: 433-444.
4. Sacks D, Noben-Trauth N, 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
5. Rogers KA, DeKrey GK, Mbow LM, Gillespie RD, Brodskyn CI, Titus RG, 2002. Type 1 and type 2 responses to Leishmania major. FEMS Microbiol Lett 209: 1-7.
6. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK, 1993. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 177: 1505-1509.
7. Sypek JP, Chung CL, Mayor SEH, Subramanyam JM, Goldman SJ, Sieburth DS, Wolf SF, Schaub RG, 1993. Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 177: 1797-1802.
8. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL, 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
9. Tonui WK, Mejia JS, Hochberg L, Mbow ML, Ryan JR, Chan AST, Martin SK, Titus RG, 2004. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major. Infect Immun 72: 5654-5661.
10. Titus RG, Lima GC, Engers HD, Louis JA, 1984. Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major-specific delayed-type hypersensitivity. J Immunol 133: 1594-1600.
11. Sacks DL, Perkins PV, 1984. Identification of an infective stage of Leishmania promastigotes. Science 223: 1417-1419.
12. Cui L, Rajasekariah GR, Martin SK, 2001. A nonspecific nucleoside hydrolase from Leishmania donovani: implications for purine salvage by the parasite. Gene 12: 153-162.
13. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P, 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263: 235-237.
14. Lima HC, Bleyenberg J, Titus RG, 1997. A simple method for quantifying Leishmania in tissues of infected animals. Parasitol Today 13: 80-82.
15. Maryanski JL, van Snick J, Cerrotini JC, Boon T, 1982. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P 815.III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur J Immunol 12: 401-406.
16. Soares MBP, David JR, Titus RG, 1997. An in vitro model for infection with Leishmania major that mimics the immune response in mice. Infect Immun 65: 2837-2845.
17. Noben-Trauth N, Kropf P, Muller I, 1996. Susceptibility to Leish mania major infection in interleukin-4-deficient mice. Science 271: 987-990.
18. Groux H, Cottrez F, Rouleau M, Mauze S, Antonenko S, Hurst S, McNeil T, Bigler M, Roncarolo MG, Coffman RL, 1999. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol 162: 1723-1729.
19. Kane MM, Mosser DM, 2001. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 166: 1141-1147.
20. Rajasekariah GR, Ryan JR, Hillier SR, Yi L, Stiteler JW, Cui L, Smithyman AM, Martin SK, 2001. Optimisation of an ELISA for the serodiagnosis of visceral leishmaniasis using in vitro derived promastigote antigens. J Immunol Methods 252: 105-119.
21. Santana DM, Borja-Cabrera GP, Paraguai de Souza E, Sturm NR, Palatnik de Sousa CB, Campbell DA, 2002. Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis. Mol Biochem Parasitol 120: 315-319.
22. Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M, Garcia-Miss Mdel R, Palatnik de Sousa CB, Dumonteil E, 2005. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 73: 812-819.
23. Gamboa-Leon R, Paraguai de Souza E, Borja-Cabrera GP, Santos FN, Myashiro LM, Pinheiro RO, Dumonteil E, Palatnikde-Sousa CB, 2006. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani. Vaccine 24: 4863-4873.
24. Shi W, Schramm VL, Almo SC, 1999. Nucleoside hydrolase from Leishmania major. Cloning, expression, catalytic properties, transition state inhibitors, and the 2.5A crystal structure. J Biol Chem 274: 21114-21120.
25. Titus RG, Marchand M, Boon T, Louis JA, 1985. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 7: 545-555.
26. Nabors GS, Afonso LC, Farrell JP, Scott P, 1995. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and pentostam. Proc Natl Acad Sci U S A 92: 3142-3146.
27. Nelson KG, Bishop JV, Ryan RO, Titus R, 2006. Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice. Antimicrob Agents Chemother 50: 1238-1244.
28. Janeway CA, Travers P, Walport M, Shlomchik MJ, 2005. Immunobiology, the Immune System in Health and Disease. New York: Garland, 16-100.
29. Becker I, Salaiza N, Aguirre M, Delgado J, Carrillo-Carrasco N, Kobeh LG, Ruiz A, Cervantes R, Torres AP, Cabrera N, Gonzalez A, Maldonado C, Isisbasi A, 2003. Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol 130: 65-74.
30. de Veer MJ, Curtis JM, Baldwin TM, DiDonato JA, Sexton A. McConville MJ, Handman E, Schofield L, 2003. MyD88 is essential for clearance of Leishmania major: Possible role for lipophosphoglycan and Toll-like receptor 2 signalling. Eur J Immunol 33: 2822-2831.
31. Kropf P, Freudenberg MA, Modolell M, Price HP, Herath S. Antoniazi S, Galanos C, Smith DF, Muller I, 2004. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immun 72: 1920-1928.
32. Flandin JF, Chano F, Descoteaux A, 2006. RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-gamma-primed macrophages. Eur J Immunol 36: 411-420.
33. Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, Webb JR, Campos-Neto A, Reed SG, 2002. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 10: 3292-3303.